FTC, states say Martin Shkreli violated lifetime pharma ban in contempt claim

• Shkreli was banned for life from the pharma industry in 2022 after a court found he organized an anticompetitive scheme that perpetuated his company's monopoly on Daraprim, an anti-parasitic drug
• The contempt allegations include publicly trading pharmaceutical stocks and broadcasting opinions about pharma companies' business and management since his prison release in May 2022
• FTC's Bureau of Competition director emphasized the action serves as notice that the agency will enforce court order violations, particularly when conduct drives up prescription drug costs

Summary: FTC Alleges Shkreli Violated Lifetime Pharma Industry Ban

The Federal Trade Commission (FTC) and seven states filed a contempt motion Tuesday against Martin Shkreli, alleging he "flagrantly and repeatedly violated" a 2022 lifetime ban from the pharmaceutical industry.

Key Violations:

Since his prison release in May 2022, Shkreli allegedly breached the court order by publicly trading pharmaceutical stocks and broadcasting opinions about pharma companies' business operations and management.

Background:

The original 2022 court order resulted from findings that Shkreli orchestrated an anti-competitive scheme to maintain his company's monopoly on Daraprim, an anti-parasitic drug. The conduct was found to have increased prescription drug costs for patients while blocking lower-cost generic alternatives from entering the market.

Regulatory Response:

Daniel Guarnera, director of the FTC's Bureau of Competition, emphasized that defendants must fulfill obligations when court judgments are entered, whether through settlement or trial orders. He stated the action signals the FTC's commitment to enforcing court order violations.

Market Context:

Shkreli, dubbed "Pharma bro," gained notoriety for extreme drug price increases and was previously convicted on securities fraud charges. The case underscores ongoing regulatory scrutiny of pharmaceutical industry practices and anti-competitive behavior that impacts drug pricing.

Implications:

This enforcement action demonstrates heightened regulatory vigilance over banned individuals attempting to circumvent industry prohibitions. It may set precedent for stricter monitoring of lifetime industry bans and signal potential consequences for similar violations in the pharmaceutical sector.